Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 253 is a member of the zinc finger protein family, characterized by the presence of Cys2His2-type zinc finger motifs that mediate binding to specific DNA sequences. It is predicted to enable DNA-binding transcription factor activity, specifically RNA polymerase II cis-regulatory region sequence-specific DNA binding, and appears to be involved in the regulation of DNA-templated transcription. Some functional evidence also suggests transcriptional repression activity. The protein is predominantly localized in the nucleus. ZNF253 has been associated with rare genetic conditions such as hypertrichosis universalis congenita, Ambras type. There are no well-established disease roles beyond gene-disease associations, nor known drug interactions or established biomarker applications for this target at present[2][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 253 (ZNF253).